<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2" class="table-wrap">
 <label class="label">Table 2</label>
 <caption class="caption">
  <p class="p">List of studies reporting candidate biomarkers for herb and spice intake</p>
 </caption>
 <table frame="hsides" rules="groups" class="table">
  <thead class="thead">
   <tr class="tr">
    <th class="th">Dietary factor</th>
    <th class="th">Study design</th>
    <th class="th">Subjects</th>
    <th class="th">Analytical method</th>
    <th class="th">Sample type</th>
    <th class="th">Discriminating metabolites/candidate biomarkers</th>
    <th class="th">Primary Ref.</th>
   </tr>
  </thead>
  <tbody class="tbody">
   <tr class="tr">
    <td class="td">Anise (anethole admn.)</td>
    <td class="td">Acute human study. [methoxy-
     <sup class="sup">14</sup>C]-labeled compound
    </td>
    <td class="td">5 (males)</td>
    <td class="td">Radiochemical (
     <sup class="sup">14</sup>C labeled) and HPLC
    </td>
    <td class="td">Urine (2 h–10 h, 24 h, and 48 h)</td>
    <td class="td">4-methoxybenzoic acid, 4-methoxyhippuric acid, 3 unknown compounds</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR36" class="xref">36</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Anise-based alcoholic drink</td>
    <td class="td">Dose escalating study (120 ml, 200 ml, 360 ml “Helenas Ouzo” (anethole-containing drink)</td>
    <td class="td">1</td>
    <td rowspan="2" class="td">HS-SPME-GC–MS</td>
    <td class="td">Serum (1, 2, 4, 8, and 24 h)</td>
    <td rowspan="2" class="td">Anethole</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR37" class="xref">37</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Observational study: drivers under the influence of alcoholic-containing anethole drink</td>
    <td class="td">50</td>
    <td class="td">Serum</td>
   </tr>
   <tr class="tr">
    <td class="td">
     <italic class="italic">Capsicum</italic> sp. Chili pepper (capsule)
    </td>
    <td class="td">Acute crossover study (5 g of capsicum extract)</td>
    <td class="td">12 (males)</td>
    <td class="td">HPLC</td>
    <td class="td">Plasma</td>
    <td class="td">Capsaicin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR41" class="xref">41</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">
     <italic class="italic">Capsicum</italic> sp. CH-19 sweet non-pungent red pepper (capsule)
    </td>
    <td class="td">Double-blind, randomized, placebo-controlled, dose-escalating (15 or 30 mg capsinoids extract)</td>
    <td class="td">24 (males)</td>
    <td class="td">LC-MS/MS and HPLC-UV</td>
    <td class="td">Plasma (15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h)</td>
    <td class="td">Capsiate, dihydrocapsiate, nordihydrocapsiate, vanillyl alcohol</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR150" class="xref">150</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">
     <italic class="italic">Capsicum</italic> sp. Paprika carotenoids
    </td>
    <td class="td">Case study. 200 ml paprika carotenoid beverage</td>
    <td class="td">5 (young, healthy)</td>
    <td class="td">HPLC-UV-VIS and Q-TOF-MS/MS</td>
    <td class="td">Plasma (0 week, 2 weeks, 4 weeks), erythrocytes</td>
    <td class="td">β-cryptoxanthin, cucurbitaxanthin A, cryptocapsin, lutein, zeaxanthin, capsanthin, capsanthone</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR42" class="xref">42</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Cinnamon</td>
    <td class="td">Four-way crossover study</td>
    <td class="td">24</td>
    <td class="td">HPLC MS/MS</td>
    <td class="td">Plasma and urine</td>
    <td class="td">7-hydroxycoumarin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR48" class="xref">48</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Fennel (fennel tea)</td>
    <td class="td">Single-dose acute study (500 ml of fennel tea)</td>
    <td class="td">7</td>
    <td rowspan="2" class="td">LC-MS/MS and GC-GC-MS</td>
    <td class="td">Urine (1.5, 4, 8, 14, 24 h)</td>
    <td rowspan="2" class="td">Estragole, 1′-hydroxyestragole, 
     <italic class="italic">trans</italic>-Anethole, -Allylphenol-G
    </td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR63" class="xref">63</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Dose-escalation study (250, 500, 1000 ml fennel tea).</td>
    <td class="td">1</td>
    <td class="td">Plasma (0.75,1.5, 2, 2.5 h)</td>
   </tr>
   <tr class="tr">
    <td class="td">Fennel, basil, and tarragon</td>
    <td class="td">15 mL fennel extract; 15 ml tarragon extract; 15 ml basil brewed</td>
    <td class="td">NP</td>
    <td class="td">IS-R-DLLME and HPLC</td>
    <td class="td">Plasma (2 h, 4 h, and 8 h) and Urine (3 h, 6 h, and 9 h)</td>
    <td class="td">
     <italic class="italic">Para</italic>-anisaldehyde 
     <italic class="italic">trans</italic>-anethole estragole
    </td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR38" class="xref">38</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="3" class="td">Ginger (extract)</td>
    <td class="td">Acute single dose: 2 g ginger extracts</td>
    <td class="td">9 (healthy)</td>
    <td rowspan="3" class="td">LC-MS/MS</td>
    <td class="td">Plasma (0.25 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 6 h, 10 h, 24 h, 48 h, and 72 h)</td>
    <td class="td">
     <p class="p">10-Gingerol, 6-Shogaol,</p>
     <p class="p">6-Gingerol-G, 8-Gingerol-G</p>
     <p class="p">10-Gingerol-G, 6-Shogaol-G</p>
     <p class="p">6-Gingerol-S, 8-Gingerol-S,</p>
     <p class="p">10-Gingerol-S, 6-Shogaol-S</p>
    </td>
    <td rowspan="3" class="td">[
     <xref ref-type="bibr" rid="CR70" class="xref">70</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Multiple dose: 24-day randomized controlled trial. 250 mg ginger extract</td>
    <td class="td">30 (healthy)</td>
    <td class="td">Plasma (0–24 h) and colon (biopsy)</td>
    <td class="td">6-Gingerol-G (plasma), 10-Gingerol-G (plasma), 6-Gingerol-S (plasma), 10-Gingerol-G (colon), 10-Gingerol-S (colon)</td>
   </tr>
   <tr class="tr">
    <td class="td">Multiple dose: 24-day randomized controlled trial. 250 mg ginger extract</td>
    <td class="td">20 (high-risk colorectal cancer)</td>
    <td class="td">Plasma (0-24 h) and colon (biopsy)</td>
    <td class="td">6-Gingerol-G (plasma), 10-Gingerol-G (plasma), 6-Gingerol-S (plasma) 10-Gingerol-G (colon), 10-Gingerol-S (colon)</td>
   </tr>
   <tr class="tr">
    <td class="td">Ginger</td>
    <td class="td">Dose escalation study: 100 mg, 250 mg, 500 mg, 1 g, 1.5 g, 2 g ginger extract (capsule)</td>
    <td class="td">27 (healthy)</td>
    <td class="td">HPLC-ECD, HPLC-UV</td>
    <td class="td">Plasma (15 min, 30 min, and 45 min, 1 h, 2 h, 4 h, 6 h, 10 h, 24 h, 48 h, and 72 h)</td>
    <td class="td">6-Gingerol-G, 8-Gingerol-G, 10-Gingerol-G, 6-Shogaol-G, 6-Gingerol-S, 10-Gingerol-S</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR69" class="xref">69</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Ginger (ginger tea)</td>
    <td class="td">Acute study. 2× (18 g/bag) ginger tea 
     <italic class="italic">(</italic>focused on the metabolism of shogaol)
    </td>
    <td class="td">3 (healthy males)</td>
    <td class="td">LC/ESI-MS/MS</td>
    <td class="td">Urine (0–2 h, 2–4 h, 4–6 h, 6–9 h, 9–12 h, and 12–24 h)</td>
    <td class="td">5-Cys-6S, 5-NAC-6S, 5-Cys-Gly-6S, 5-Cys-M6, 5-NAC-M6, 5-Cys-Gly-M6, 5-Cys-8S, 5-Cys-M6’, 5-Cys-10S, 5-Cys-M6"</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR71" class="xref">71</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Marjoram (extract)</td>
    <td class="td">Acute single oral dose (3.75 g) of 
     <italic class="italic">O. onites</italic> extract
    </td>
    <td class="td">6 (healthy)</td>
    <td class="td">HPLC-CEAD</td>
    <td class="td">Urine (24 h, 48 h)</td>
    <td class="td">Protocatechuic acid, 
     <italic class="italic">p</italic>-hydroxybenzoic acid, caffeic acid, ferulic acid, syringic acid, vanillic acid, 
     <italic class="italic">p</italic>-coumaric acid, 3,4-dihydroxyphenylacetic acid, 
     <italic class="italic">m</italic>-hydroxyphenylacetic acid
    </td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR97" class="xref">97</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Nutmeg</td>
    <td class="td">Acute oral dose in rats (100 mg/kg body mass) of EL, MY, and SA or a single 500 mg/kg body mass of nutmegs</td>
    <td class="td">2 rats × each substance and dose</td>
    <td rowspan="2" class="td">GC-MS</td>
    <td rowspan="2" class="td">Urine (24 h)</td>
    <td rowspan="2" class="td">O-demethyl elemicin
     <sup class="sup">*</sup>, O-demethyl dihydroxy elemicin
     <sup class="sup">*</sup>, demethylenyl myristicin
     <sup class="sup">*</sup>, dihydroxy myristicin
     <sup class="sup">*</sup>, demethylenyl safrole
     <sup class="sup">*</sup>
    </td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR73" class="xref">73</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Observational exploratory toxicological study: after nutmeg abuse (~ 5 nutmegs)</td>
    <td class="td">1</td>
   </tr>
   <tr class="tr">
    <td class="td">Oregano (extract)</td>
    <td class="td">Oregano extract (25, 75, or 225 mg/kg</td>
    <td class="td">15 mice</td>
    <td class="td">HPLC–MS/MS</td>
    <td class="td">Plasma and brain tissue</td>
    <td class="td">Carvacrol</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR95" class="xref">95</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Parsley</td>
    <td class="td">Randomized crossover with two 1-week intervention periods in succession, supplemented with parsley 20 g parsley/MJ</td>
    <td class="td">14 (healthy)</td>
    <td class="td">HPLC-DAD</td>
    <td class="td">Urine (24 h)</td>
    <td class="td">Apigenin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR108" class="xref">108</xref>, 
     <xref ref-type="bibr" rid="CR109" class="xref">109</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Parsley</td>
    <td class="td">Acute human study. (149.45 ± 35.21 g parsley)</td>
    <td class="td">11 (healthy)</td>
    <td class="td">HPLC-ECD</td>
    <td class="td">Plasma (4–11 h, 28 h), urine (24 h), and red blood cells</td>
    <td class="td">Apigenin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR102" class="xref">102</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Peppermint oil (capsule)</td>
    <td rowspan="2" class="td">Acute pharmacokinetic study. Intake of 0.4 ml peppermint oil in either colpermin or gelatine capsules (91–97 mg capsule)</td>
    <td class="td">6 (healthy)</td>
    <td rowspan="2" class="td">NP</td>
    <td rowspan="2" class="td">Urine (24 h)</td>
    <td rowspan="2" class="td">Menthol-G</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR117" class="xref">117</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">6 (ileostomy)</td>
   </tr>
   <tr class="tr">
    <td class="td">Peppermint oil</td>
    <td class="td">Acute randomized intake of 0.6 ml peppermint oil in either 
     <italic class="italic">Colpermin</italic> or 
     <italic class="italic">Mintec</italic> preparations
    </td>
    <td class="td">13 (healthy)</td>
    <td class="td">GC-MS</td>
    <td class="td">Urine (2 h-interval for 14 h + single overnight (10 h)</td>
    <td class="td">Menthol-G</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR116" class="xref">116</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Peppermint oil (capsule)</td>
    <td class="td">180 mg peppermint oil enteric-coated capsule (peroral administration)</td>
    <td class="td">4 (males)</td>
    <td class="td">GC-FID</td>
    <td class="td">Urine (2-h interval up to 14 h)</td>
    <td class="td">Menthol-G</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR118" class="xref">118</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Peppermint oil (capsule)</td>
    <td class="td">Acute (400 mg peppermint oil in enteric-coated capsule) and repeated 4 weeks later</td>
    <td class="td">5 (healthy)</td>
    <td class="td">
     <sup class="sup">2</sup>H-NMR
    </td>
    <td class="td">Urine (2 h, 4 h, 6 h, and 8 h)</td>
    <td class="td">Menthol-G</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR120" class="xref">120</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Peppermint oil (capsule)</td>
    <td class="td">(1) 400 mg of enteric-coated peppermint oil capsules and 6 g of 99% [U-
     <sup class="sup">13</sup>C] glucose
    </td>
    <td class="td">1 (female)</td>
    <td rowspan="2" class="td">
     <sup class="sup">13</sup>C-NMR
    </td>
    <td class="td">Urine (2-4 h)</td>
    <td rowspan="2" class="td">
     <sup class="sup">13</sup>C-menthol-G
    </td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR119" class="xref">119</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">(2) Primed infusion of [U-
     <sup class="sup">13</sup>C] glucose + 400 mg enteric-coated peppermint oil capsules
    </td>
    <td class="td">4 (severe heart failure)</td>
    <td class="td">Urine (2 h)</td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Peppermint oil (L-menthol preparation)</td>
    <td rowspan="2" class="td">Escalating-single-dose, randomized, double-blind, placebo-controlled (menthol preparation, 80–320 mg). Intragastric spraying of peppermint oil</td>
    <td rowspan="2" class="td">24 (males)</td>
    <td rowspan="2" class="td">GC-MS</td>
    <td class="td">Plasma (5, 10, 30, 60, 120, and 240 min and 8, 12, and 24 h after each dose)</td>
    <td class="td">Menthol, menthol-G, M7, M9, M11, M29</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR121" class="xref">121</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Urine (before dosing (−12–0 h) and 0–4 h, 4–8 h, 8–12 h, and 12–24 h after</td>
    <td class="td">Menthol-G, M2, M3–11, M12, M13–18, M19–21, M22–28, M29, M30–32.</td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Rosemary (extract)</td>
    <td class="td">Acute, controlled, randomized study. Rosemary extract enriched in carnosic acid 40% (
     <italic class="italic">w</italic>/
     <italic class="italic">w</italic>)
    </td>
    <td rowspan="2" class="td">24 Zucker rats</td>
    <td rowspan="2" class="td">HPLC/QTOF-MS and HPLC-UV</td>
    <td rowspan="2" class="td">Gut, liver, plasma, brain,</td>
    <td rowspan="2" class="td">Carnosic acid-G, carnosol-G, rosmanol-G, carnosic acid 12 methyl ether, 5,6,7,10-tetrahydro-7-hydroxyrosmariquinone, carnosic glutathione oxidized, carnosol-S, rosmanol-S, rosmarinic acid, carnosic cysteine, carnosic glutathione, rosmadial-G, rosmanol, ipirosmanol, epiisorosmanol, rosmadial/rosmanol quinone, rosmanol/epirosmanol methyl ether, carnosol, rosmadial methyl ether, epirosmanol ethyl ether, epiisorosmanol methyl ether, carnosol methyl ether, carnosic acid.</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR100" class="xref">100</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Subchronic, controlled, randomized study Rosemary extract enriched in carnosic acid 40% (
     <italic class="italic">w</italic>/
     <italic class="italic">w</italic>) (64 days)
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Saffron (tea)</td>
    <td class="td">Single-dose acute study. 200 mg saffron in 150 ml water (saffron tea)</td>
    <td class="td">4 (healthy)</td>
    <td class="td">SPE-HPLC-DAD</td>
    <td class="td">Plasma (0 h, 2 h, and 24 h)</td>
    <td class="td">
     <italic class="italic">cis-</italic>Crocetin, 
     <italic class="italic">trans-</italic>Crocetin
    </td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR126" class="xref">126</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Saffron (purified crocetin)</td>
    <td class="td">Open-label, single dose escalation of crocetin (7.5, 15 and 22.5 mg)</td>
    <td class="td">10 (healthy)</td>
    <td class="td">HPLC</td>
    <td class="td">Plasma (1 , 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h)</td>
    <td class="td">Crocetin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR127" class="xref">127</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Sage (tea)</td>
    <td class="td">Acute human study (1.02 mg 1,8-cineole) in sage tea</td>
    <td class="td">1 (female)</td>
    <td class="td">SPME-GC-MS and LC-MS/MS</td>
    <td class="td">Plasma (0.75 h, 1.7 h, 3.25 h, 6.75 h, and 24 h) and urine (2 h, 5 h, 7 h, 10 h, 17 h, 21 h, 28 h, 32 h, 35 h, 44 h, 50 h, 53 h, 60 h, and 69 h)</td>
    <td class="td">1,8-cineole, 2-hydroxy-1,8-cineole, 3-hydroxy-1,8-cineole, 7-hydroxy-1,8-cineole, 9-hydroxy-1,8-cineole.</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR130" class="xref">130</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Thyme (tablet)</td>
    <td rowspan="2" class="td">Acute study. A single dose of a Bronchipret® TP (tablet equivalent to 1.08 mg thymol)</td>
    <td rowspan="2" class="td">12</td>
    <td rowspan="2" class="td">HS-SPME-GC-MS and LC-MS/MS</td>
    <td class="td">Plasma (0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, 12 h, 14 h, 24 h, 31 h, 38 h, 48 h, 55 h, 62 h, and 72 h)</td>
    <td class="td">Thymol-S</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR151" class="xref">151</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Urine (0 to 3 h, 3 to 6 h, 6 to 9 h, 9 to 14 h, 14 to 24 h, 24 to 31 h, 38 to 48 h, 48 to 55 , 55 to 62 h, and 62 to 72 h)</td>
    <td class="td">Thymol-G, thymol-S</td>
   </tr>
   <tr class="tr">
    <td class="td">Thyme</td>
    <td class="td">Acute intake of 1.5 g of thyme extract</td>
    <td class="td">12 Wistar rats</td>
    <td class="td">μSPE-UPLC-MS/MS</td>
    <td class="td">Plasma</td>
    <td class="td">Thymol-S, thymol-G, luteolin-S, luteolin-G, hydroxyphenylpropionic acid-S, coumaric acid-S, caffeic acid-S, ferulic acid-S, ferulic acid-G, hydroxybenzoic acid, and dihydrophenylpropionic acid-S</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR98" class="xref">98</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Thyme (olive oil enriched with thyme polyphenols)</td>
    <td rowspan="2" class="td">Randomized, double-blind, controlled, cross-over trial. Administration of 25 ml/day (VOO)/VOO + PC/VOO + PC + PC of thyme</td>
    <td rowspan="2" class="td">33 (hypercholesterolemic)</td>
    <td rowspan="2" class="td">μSPE-UPLC-ESI-MS/MS</td>
    <td class="td">Plasma</td>
    <td class="td">Thymol-S, hydroxyphenylpropionic acid-S, caffeic acid-S</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR99" class="xref">99</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Urine (24 h)</td>
    <td class="td">Thymol-S, Thymol-G, hydroxyphenylpropionic acid-S, 
     <italic class="italic">p</italic>-cymene-diol-G, caffeic acid-S
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="5" class="td">Thyme (olive oil enriched with thyme)</td>
    <td rowspan="4" class="td">(1) In vitro colonic fermentation (0 to 48 h)</td>
    <td rowspan="4" class="td">3 (healthy)</td>
    <td rowspan="5" class="td">UPLC-ESI-MS/MS and GC-FID</td>
    <td rowspan="4" class="td">Feces (in vitro fermentation)</td>
    <td class="td">Thymol, carvacrol, 2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid, phenylacetic acid, 3-(4′-hydroxyphenyl) propionic acid, phenylpropionic acid.</td>
    <td rowspan="5" class="td">[
     <xref ref-type="bibr" rid="CR96" class="xref">96</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid, Phenylacetic acid, 3-(4′-hydroxyphenyl) propionic acid, phenylpropionic acid</td>
   </tr>
   <tr class="tr">
    <td class="td">Caffeic acid, 
     <italic class="italic">p</italic>-coumaric acid, 3-(3′, 4′-dihydroxyphenyl) propionic acid; hydroxyphenylpropionic acid; phenylpropionic acid, 2-(3′,4′-dihydroxyphenyl) acetic acid; 2-(4′-hydroxyphenyl) acetic acid; phenylacetic acid
    </td>
   </tr>
   <tr class="tr">
    <td class="td">3-(3′, 4′-dihydroxyphenyl) propionic acid; hydroxyphenylpropionic acid; phenylpropionic acid, 2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid; phenylacetic acid</td>
   </tr>
   <tr class="tr">
    <td class="td">(2) Human intervention study: 25 ml/day of a thyme phenol-enriched olive oil for 3 weeks</td>
    <td class="td">10</td>
    <td class="td">Feces (in vivo
     <italic class="italic">,</italic> (0-3wk)
    </td>
    <td class="td">Carvacrol, 2-(4-hydroxyphenyl) acetic acid, 3-(3′-4′-dihydroxyphenyl) propionic acid, hydroxyphenylpropionic acid, phenylpropionic acid</td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">Randomized double blind placebo (1 g/day, 4 g/day, placebo), 6 months</td>
    <td class="td">31 (elderly)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma (2–2.5 h after 1 month)</td>
    <td class="td">Curcumin, DMC BDMC, THC, ferulic acid, vanillic acid</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR132" class="xref">132</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">Acute study</td>
    <td class="td">2 (healthy)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma</td>
    <td class="td">COG</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR141" class="xref">141</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoidsin nanoemulsion)</td>
    <td class="td">Acute study (2 g nanoemulsion curcuminoids)</td>
    <td class="td">2 (healthy)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma</td>
    <td class="td">Curcumin, COG, COS, DMC, BDMC, and THC</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR142" class="xref">142</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">Nonrandomized, open-label, phase II trial (starting dose 8 g curcuminoids) 8 weeks</td>
    <td class="td">25 (pancreatic cancer)</td>
    <td class="td">LC-MS</td>
    <td class="td">Plasma (1 h, 2 h, 6 h, 24 h, 48 h, 72 h, day 8 and after 4 weeks</td>
    <td class="td">COG and COS</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR140" class="xref">140</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">Dose escalation. 450–3600 mg/day 1 week</td>
    <td class="td">12 (hepatic metastasis from colorectal cancer)</td>
    <td class="td">HPLC-UV, LC-MS</td>
    <td class="td">Plasma and liver tissue</td>
    <td class="td">Hexahydrocurcumin (liver), hexahydrocurcuminol (liver), curcumin (plasma), COG (plasma), COS (plasma).</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR143" class="xref">143</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">Acute study.</td>
    <td class="td">12 (colorectal carcinoma)</td>
    <td class="td">HPLC-UV HPLC-MS</td>
    <td class="td">Plasma and colorectal tissue</td>
    <td class="td">Curcumin (plasma and colorectal tissue), COG and COS (colorectal tissue)</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR6" class="xref">6</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids-different administration types)</td>
    <td class="td">Randomized double blind crossover study with formulated (CP, CTR, CHC) and unformulated (CS) curcumin</td>
    <td class="td">12 (healthy)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma (1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, and 12 h)</td>
    <td class="td">Curcumin, DMC, BDMC, THC</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR138" class="xref">138</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuminoids in capsule)</td>
    <td class="td">14-day intervention (2.35 g capsule)</td>
    <td class="td">24 (colorectal cancer)</td>
    <td class="td">UPLC-UV, LC-MS/MS</td>
    <td class="td">Plasma, urine and colon tissue</td>
    <td class="td">Curcumin, BDMC, DMC, BDMC-S, DMC-S, COS, COG, BDMC-G, DMC-G</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR147" class="xref">147</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (Theracurmin®)</td>
    <td class="td">Acute dose escalation 150 mg and 210 mg</td>
    <td class="td">6 (healthy)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma (0 h, 1 h, 2 , 4 h, 6 , 24 h)</td>
    <td class="td">Curcumin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR152" class="xref">152</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (Theracurmin®)</td>
    <td class="td">Multi-week dose escalation</td>
    <td class="td">16 (pancreatic or biliary tract cancer)</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma (2 h)</td>
    <td class="td">Curcumin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR153" class="xref">153</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Turmeric (turmeric fresh derived curcuminoids vs. std. curcumin)</td>
    <td class="td">Multi-week double crossover study. 250 mg/kg body weight</td>
    <td class="td">18 (mice)</td>
    <td rowspan="2" class="td">LC-DAD-ESI-MS/MS</td>
    <td rowspan="2" class="td">Plasma (0 h, 0.5 , 1 h, 3 h, 5 h, 8 h, 12 h)</td>
    <td rowspan="2" class="td">Curcumin, DMC, BMDC</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR149" class="xref">149</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Acute, single-blind crossover study, 100 mg, 250 mg, 1000 mg</td>
    <td class="td">15 (healthy)</td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Turmeric (C3 complex)</td>
    <td class="td">Acute study. 1 single dose (4 g)</td>
    <td class="td">8 (healthy)</td>
    <td rowspan="2" class="td">HPLC</td>
    <td rowspan="2" class="td">Serum</td>
    <td rowspan="2" class="td">Curcumin</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR154" class="xref">154</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">3–4-week intervention study. (8 g/day)</td>
    <td class="td">15 (with HNSCC)</td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcuma extract capsule)</td>
    <td class="td">Dose escalation: 440 mg–2200 mg/day. 4 months</td>
    <td class="td">15 (colorectal cancer)</td>
    <td class="td">HPLC-UV</td>
    <td class="td">Blood, urine, feces</td>
    <td class="td">COS (only detected in feces)</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR25" class="xref">25</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (C3 complex)</td>
    <td class="td">Dose escalation study. 4-month intervention (450, 900, 1800, 3600 mg). 4 months</td>
    <td class="td">15 (colorectal adenocarcinoma patients)</td>
    <td class="td">LC-MS</td>
    <td class="td">Plasma, urine, feces</td>
    <td class="td">Curcumin (plasma, urine, feces), COG (plasma, urine), DMC (plasma, urine), BDMC (plasma), DMC-G (plasma, urine), DMC-S (plasma) COS (plasma, urine, and feces).</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR145" class="xref">145</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (C3 complex, 10 or 12 g)</td>
    <td class="td">Acute study</td>
    <td class="td">12 (healthy)</td>
    <td class="td">HPLC</td>
    <td class="td">Plasma</td>
    <td class="td">COG and COS</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR139" class="xref">139</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td rowspan="2" class="td">Turmeric</td>
    <td rowspan="2" class="td">3-month intervention with different doses each group (500, 1000, 2000, 4000, 8000 mg/day)</td>
    <td rowspan="2" class="td">25 cancer</td>
    <td rowspan="2" class="td">HPLC-UV</td>
    <td class="td">Serum (0 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 12 h, 14 h, and 24 h)</td>
    <td rowspan="2" class="td">Curcumin (only in serum)</td>
    <td rowspan="2" class="td">[
     <xref ref-type="bibr" rid="CR144" class="xref">144</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Urine (0–2 h, 2–4 h, 4–8 h, and 8–24 h)</td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (Theracurmin®)</td>
    <td class="td">Acute study. Curcumin in powder and Theracurmin® in liquid (30 mg).</td>
    <td class="td">12 Sprague-Dawley rats and 14 humans</td>
    <td class="td">LC-MS/MS</td>
    <td class="td">Plasma</td>
    <td class="td">Theracurmin and curcumin</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR148" class="xref">148</xref>]
    </td>
   </tr>
   <tr class="tr">
    <td class="td">Turmeric (curcumin)</td>
    <td class="td">Dose escalation study. C3 complex adm. 500 mg, 1000 mg, 2000 mg, 4000 mg, 6000 mg, 8000 mg, 10,000 mg, and 12,000 mg)</td>
    <td class="td">24</td>
    <td class="td">HPLC</td>
    <td class="td">Plasma and serum</td>
    <td class="td">Curcumin (just in serum at 10000 and 12,000 mg)</td>
    <td class="td">[
     <xref ref-type="bibr" rid="CR146" class="xref">146</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot class="table-wrap-foot">
  <p class="p">
   <italic class="italic">Adm</italic>, administration; 
   <italic class="italic">BDMC</italic>, bisdemethoxycurcumin, 
   <italic class="italic">CEAD</italic>, coulometric electrode array detector; 
   <italic class="italic">CHC</italic>
   <bold class="bold">,</bold> combination of hydrophilic carrier, cellulosic derivatives, and natural antioxidants; 
   <sup class="sup">
    <italic class="italic">13</italic>
   </sup>
   <italic class="italic">C-NMR</italic>
   <bold class="bold">,</bold> carbon nuclear magnetic resonance; 
   <italic class="italic">COG</italic>, curcumin-O-glucoronide. 
   <italic class="italic">COS</italic>, curcumin-O-sulfate; 
   <italic class="italic">CP</italic>, curcumin phytosome formulation; 
   <italic class="italic">CS</italic>, standardized curcumin mixture; 
   <italic class="italic">CTR</italic> formulation with volatile oils of turmeric rhizome, 
   <italic class="italic">Cys</italic>, cysteinyl; 
   <italic class="italic">DAD</italic>, diode array detector; 
   <italic class="italic">DMC</italic>, demethoxycurcumin, 
   <italic class="italic">ECD</italic>, electrochemical detection. 
   <italic class="italic">EL</italic>, elemicin; 
   <italic class="italic">ESI</italic>
   <bold class="bold">,</bold> electrospray ionization; 
   <italic class="italic">FID</italic>
   <bold class="bold">,</bold> flame ionization detector; 
   <italic class="italic">−G</italic>, glucuronide; 
   <italic class="italic">Gly</italic>, glycinyl; 
   <italic class="italic">H-NMR</italic>, proton nuclear magnetic resonance; 
   <italic class="italic">HPLC</italic>, high-performance liquid chromatography; 
   <italic class="italic">HNSCC</italic> head and neck squamous cell carcinomas; 
   <italic class="italic">HS-SPME</italic>, headspace solid-phase microextraction; 
   <italic class="italic">IS-R-DLLME</italic>, in-syringe reversed dispersive liquid-liquid microextraction; 
   <italic class="italic">LC</italic>, liquid chromatography; 
   <italic class="italic">months</italic>, months; 
   <italic class="italic">MJ</italic>, megajoules; 
   <italic class="italic">MY</italic>, myristicin, 
   <italic class="italic">M6</italic>
   <bold class="bold">,</bold> 1-(4′-hydroxy-3′-methoxyphenyl)-4-decen-3-ol; 
   <italic class="italic">M6′</italic>, 1-(4′-hydroxy-3′-methoxyphenyl)-4-dodecen-3-ol; 
   <italic class="italic">M6′′</italic>, 1-(4′-hydroxy-3′-methoxyphenyl)-4-tetradecen-3-ol; 
   <italic class="italic">M29</italic>, menthol sulfoconjugate; 
   <italic class="italic">M7, 9, 11</italic>, hydroxyl menthol glucuronide. 
   <italic class="italic">M3–11</italic>, hydroxyl menthol glucuronide; 
   <italic class="italic">M19–21</italic>, dihydroxyl menthol glucuronide. 
   <italic class="italic">M2</italic>, aldehyde-menthol glucuronide; 
   <italic class="italic">M13–18</italic>, carboxylate-menthol or aldehyde-hydroxyl menthol glucuronide; 
   <italic class="italic">M29–32</italic>, sulfate conjugates; 
   <italic class="italic">M12</italic>, dialdehydementhol glucuronide (M12); 
   <italic class="italic">MS</italic> mass spectrometry; 
   <italic class="italic">NAC</italic>
   <bold class="bold">,</bold> N-acetylcysteinyl; 
   <italic class="italic">NP</italic>, not provided; 
   <italic class="italic">PC</italic>, phenolic compounds; 
   <italic class="italic">Q-TOF</italic>, quadrupole time-of-flight; 
   <italic class="italic">S</italic>, sulfate; 
   <italic class="italic">SA</italic>, safrole; 
   <italic class="italic">THC</italic>, tetrahydrocurcumin; 
   <italic class="italic">UPLC</italic>, ultra-high performance liquid chromatography; 
   <italic class="italic">UV</italic> ultraviolet; 
   <italic class="italic">VIS</italic>, visible; 
   <italic class="italic">VOO</italic>, virgin olive oil. weeks, week; 
   <italic class="italic">w/w</italic>, weight per weight; 
   <italic class="italic">μSPE</italic>, microelution solid-phase extraction; 
   <italic class="italic">6S</italic>, 6-shogaol; 
   <italic class="italic">8S</italic>, 8-shogaol; 
   <italic class="italic">10S</italic>, 10-shogaol
  </p>
  <p class="p">*In the study performed in rats, there were other metabolites also identified but not found in the human sample analyzed so they were not considered in this table</p>
 </table-wrap-foot>
</table-wrap>
